



## TABLE OF STATUTES AND REGULATIONS

This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or [hgray@namsdl.org](mailto:hgray@namsdl.org) with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

	<b>Drugs Monitored: Schedules II-V</b>	<b>Drugs Monitored: Non-controlled</b>	<b>Training/ Education</b>	<b>De-identified Data</b>	<b>Interstate Sharing: Other PMPs</b>	<b>Interstate Sharing: Authorized Users</b>	<b>Interstate Sharing: Both</b>
Alabama	§ 20-2-213				§ 20-2-214		
Alaska	§ 17.30.200					12 AAC 52.855	
Arizona				§ 36-2604			§ 36-2604
Arkansas	§ 20-7-603 & -604			§ 20-7-607	§ 20-7-608; ADC 007.07.4-VIII		
California				H&S § 11165		Website	
Colorado	§ 12-42.5-402 & -403			§ 12-42.5-404		§ 12-42.5-404	
Connecticut	§ 21a-254			ADC 21a-254-6			§ 21a-274; §20-578
Delaware	16 § 4798	16 § 4798		16 § 4798	16 § 4798		
District of Columbia	Sec. 2	Sec. 2		Sec. 6	Sec. 7		
Florida							
Georgia	§ 16-13-59			§ 16-13-60			
Hawaii	§ 329-102	§ 329-102			§ 329-104		
Idaho	§ 37-2726	§ 37-2726		§ 37-2730A		§ 37-2726	
Illinois	720 § 570/316	720 § 570/316		720 § 570/318	720 § 570/318; ADC 77 § 2080.211		
Indiana	§ 35-48-7-8.1			§ 35-48-7-11.1			§ 35-48-7-11.1; § 35-48-7-5.4
Iowa						§ 124.553	
Kansas		ADC 68-21-7		§ 65-1685	ADC 68-21-5&6		
Kentucky	§ 218A.202		§ 218A.202; § 218A.240	§ 218A.240			§ 218A.202; § 218A.245; § 218A.390
Louisiana	§ 40:1006	§ 40:1006	§ 40:1007 & :1008	§ 40:1007			§ 40:1007; ADC Tit. 46, Pt. LIII, §§ 2917 & 2921

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Maine				22 § 7250	22 § 7250; 22 §§ 7261 - 7274		
Maryland	Health-Gen. § 21-2A-02			Health-Gen. § 21-2A-06	Health-Gen. § 21-2A-06; ADC 10.47.07.04		
Massachusetts	94C § 24A	94C § 24A	94C § 24A	94C § 24A	94C § 24A; 105 CMR 700.012		
Michigan	§ 333.7333a						§ 333.7333a
Minnesota						§ 152.126	
Mississippi	§ 73-21-127	§ 73-21-127		§ 73-21-127	§ 73-21-127		
Missouri							
Montana	§ 37-7-101		Admin.	ADC 24.174.1713	§ 37-7-1506		
Nebraska							
Nevada			§ 453.1545	§ 453.1545	§ 453.1545		
New Hampshire					§ 318-B:35		
New Jersey	§ 45:1-45	§ 45:1-47	Admin.	§ 45:1-46			§ 45:1-46
New Mexico	ADC 16.19.29		ADC 16.19.29	ADC 16.19.29			ADC 16.19.29
New York	PH § 3343-a						PH § 3371-a
North Carolina	§ 90-113.73			§ 90-113.74	§ 90-113.74		
North Dakota	ADC 61-12-01-01 & -02	ADC 61-12-01-01 & -02		§ 19-03.5-03			§ 19-03.5-06 & -08
Ohio	§ 4729.75	§ 4729.75	ADC 4723-9-02 & -13	§ 4729.80			§ 4729.80
Oklahoma	63 § 2-309C			63 § 2-309D			
Oregon				§ 431.966			§ 431.960 & § 431.966
Pennsylvania			Admin.				
Rhode Island				§ 21-28-3.32 ADC 31-2-1:3.0	NABP		

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

South Carolina			Website	§ 44-53-1650			§ 44-53-1650
South Dakota				§ 34-20E-7	§ 34-20E-14		
Tennessee	§ 53-10-304						§§ 53-10-311, -302 & -303
Texas	H&S § 481.074			H&S § 481.076		H&S § 481.076	
Utah	§ 58-37-2		§ 58-37f-402	§ 58-37f-301; ADC R156-37f	§ 58-37f-301		
Vermont			18 § 4282; ADC 12-5-21:4	18 § 4284			18 § 4284; 18 § 4288
Virginia				§ 54.1-2523	§ 54.1-2523		
Washington	§ 70.225.020	§ 70.225.020		§ 70.225.040			ADC 246-470-070
West Virginia	ADC § 15-11-4		§ 60A-9-5	§ 60A-9-5			§ 60A-9-5 & ADC § 15-8-7
Wisconsin	ADC Pharm 18.03	§ 450.19; ADC Pharm 18.03		ADC Pharm 18.11			§ 450.19; ADC Pharm 18.11 & 18.14
Wyoming		ADC AI PDSC Ch. 8, § 7		§ 35-7-1060		§ 35-7-1060	

	<b>Unsolicited Reports</b>	<b>Data Confidentiality: Not subject to public or open records laws</b>	<b>Data Confidentiality: Penalties for disclosing data</b>	<b>Data Confidentiality: Penalties for Wrongly using data</b>	<b>Data Confidentiality: Penalties for wrongly Obtaining data</b>	<b>Mandatory Utilization</b>	<b>Mandatory Enrollment</b>
Alabama	2010 Survey	§ 20-2-215	§ 20-2-216		§ 20-2-216		§ 34-24-604; ADC 540-X-18-.05
Alaska	2009 Survey	§ 17.30.200	§ 17.30.200		§ 17.30.200		
Arizona	§ 36-2604	§ 36-2604	§ 36-2610				§ 36-2606
Arkansas	§ 20-7-607	§ 20-7-606	§ 20-7-611; ADC 007.07.4-XI	§ 20-7-611; ADC 007.07.4-XI	§ 20-7-611; ADC 007.07.4-XI		
California	H&S § 11165.1		Civ. § 56.36	Civ. §56.36	Civ. § 56.36		H&S § 11165.1
Colorado			§ 12-42.5-406		§ 12-42.5-406	2 CCR 502-1:21.320.3 & 7 CCR 1101-3:18	
Connecticut	ADC 21a-254-5						§ 21a-317
Delaware	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798
District of Columbia		Sec. 6	Sec. 10	Sec. 10			
Florida	§ 893.055	§ 893.0551					
Georgia		§ 16-13-60	§ 16-13-64	§ 16-13-64	§ 16-13-64		
Hawaii	§ 329-103	§ 329-104	§ 329-104	§ 329-104			
Idaho	§ 37-2730A		§ 37-2726		§ 37-2726		
Illinois	720 § 570/314.5						
Indiana	§ 35-48-7-11.1						
Iowa		§ 124.553	§ 124.558	§ 124.558	§ 124.558		
Kansas	§ 65-1685	§ 65-1685	§ 65-1693	§ 65-1693	§ 65-1693		

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Kentucky	§ 218A.240	§ 218A.202	§ 218A.202		§ 218A.202	§ 218A.172; 201 KAR 8:540, 9:016, 9:260, 20:057 & 25:090	§ 218A.202; 201 KAR 5:130, 9:230, 25:011 & 25:021
Louisiana	§ 40:1007	§ 40:1007	§ 40:1009	§ 40:1009		48 ADC Pt. I, § 7831	
Maine	22 § 7250	22 § 7250	22 § 7251	22 § 7251			22 § 7249
Maryland		Health-General § 21-2A-06	Health-General § 21-2A-09	Health-General § 21-2A-09	Health-General § 21-2A-09		
Massachusetts	94C § 24	94C § 24A	105 ADC 700.012	105 ADC 700.012	105 ADC 700.012	94C §24A; 105 CMR 725.010	94C § 7A
Michigan	Admin. <sup>1</sup>	§ 333.7333a					
Minnesota		§ 152.126	§ 152.126			§254A.192	
Mississippi	§ 73-21-127	§ 73-21-127				ADC 24-2:59.2	ADC 30-17- 2640:1.15
Missouri							
Montana	§ 37-7-1504		§ 37-7-1513	§ 37-7-1513			
Nebraska							
Nevada	§ 453.1545					§ 639.23507	
New Hampshire	§ 318-B:35	§ 318-B:34	§ 318-B:36	§ 318-B:36	§ 318-B:36		§ 318-B:33
New Jersey	§ 45:1-46	§ 45:1-46	§ 45:1-49	§ 45:1-49			
New Mexico	ADC 16.19.29	ADC 16.19.29	Admin.		Admin.	ADC 16.5.57, 16.10.14, 16.12.9, 16.19.4 & 16.21.9	ADC 16.5.57, 16.10.14, 16.19.20 & 16.21.9
New York	PH § 3343-a					PH § 3343-a; 10 ADC 80.63	
North Carolina	§ 90-113.74	§ 90-113.74	§ 90-113.75		§ 90-113.75	Admin.	

<sup>1</sup> Michigan sends alerts to physicians when patients surpass set thresholds, but does not send the actual report.

North Dakota	§ 19-03.5-06		§ 19-03.5-10	§ 19-03.5-10			
Ohio	§ 4729.81	§ 4729.80	§ 4729.86		§ 4729.86	Multiple statutes and regs. <sup>2</sup>	
Oklahoma	63 § 2-309G	63 § 2-309D	63 § 2-309D			63 § 2-302	
Oregon		§ 431.966	§ 431.970	§ 431.970			
Pennsylvania	18 § 9102						
Rhode Island	ADC 31-2-1:3.0				§ 21-28-3.32	ADC § 46-1-13:45.0	
South Carolina	§ 44-53-1650	§ 44-53-1650	§ 44-53-1680	§ 44-53-1680			
South Dakota	§ 34-20E-12		§ 34-20E-19				
Tennessee	§ 53-10-305	§ 53-10-306	§ 53-10-306	§ 53-10-306	§ 53-10-306	§ 53-10-310; ADC 1140-11-.06 & 1200-34-01-.07	§ 53-10-305
Texas	2010 Survey		H&S § 481.127		H&S § 481.127		
Utah	§ 58-37f-702		§ 58-37f-601	§ 58-37f-601	§ 58-37f-601		§ 58-37f-401
Vermont	18 § 4284	18 § 4284	18 § 4284		18 § 4284	18 § 4289 & 18 § 4290	18 § 4289; ADC 12-5-102:2
Virginia	§ 54.1-2523	§ 54.1-2523	§ 54.1-2525	§ 54.1-2525		§ 54.1-2522.1 (eff. July 1, 2015)	§ 54.1-2522.1 (eff. July 1, 2015)
Washington	Admin.		§ 70.225.060	§ 70.225.060		ADC 296-20-03035, 296-20-03056, & 388-877B-0440	

<sup>2</sup> OH ADC 4729-5-20; § 4731.055; ADC 4731-11-11; § 4715.302; ADC 4715-6-01; § 4723.487; ADC 4723-9-12; § 4725.092; § 4729.162; § 4730.53; ADC 4723-6-21.4

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

West Virginia	§ 60A-9-5		§ 60A-9-7	§ 60A-9-7	§ 60A-9-7	Multiple statutes and regs. <sup>3</sup>	ADC 5-10-3, 11-10-3, 19-14-3 & 24-7-3
Wisconsin	2010 Survey	ADC Pharm 18.13	ADC Pharm 18.13				
Wyoming	§ 35-7-1060						

<sup>3</sup> WV § 16-5H-4, § 60A-9-5a, ADC §§ 5-10-1, 5-10-3, 11-10-1, 11-10-3, 19-14-1, 19-14-3, 24-7-1, 24-7-3, 69-7-27, and 69-7-42.

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501



<b>Types of Authorized Recipients:</b>	<b>Coroners/ MEs</b>	<b>Licensing/ Regulatory Boards</b>	<b>Medicaid/Medicare/ State Health Ins. Programs</b>	<b>Patient or Parent of Minor</b>	<b>Prescribers &amp; Dispensers</b>	<b>Substance Abuse/ Mental Health Profs.</b>	<b>Work Comp Specialists</b>
Alabama		§ 20-2-214	§ 20-2-214		§ 20-2-214		
Alaska		§ 17.30.200		§ 17.30.200; 12 AAC 52.875	§ 17.30.200; 12 AAC 58.855		
Arizona		§ 36-2604	§ 36-2604	§ 36-2604	§ 36-2604		§ 36-2604; § 23-1026
Arkansas	§ 20-7-607; ADC 007.07.4-VII	§ 20-7-606 & -607; ADC 007.07.4-VI & -VII		§ 20-7-607; ADC 007.07.4-VII	§ 20-7-607; ADC 007.07.4-VII		
California		H&S § 11165			H&S § 11165.1		
Colorado		§ 12-42.5-404; ADC 719-1:23.00.00		§ 12-42.5-404; ADC 719-1:23.00.00	§ 12-42.5-404; ADC 719-1:23.00.00		
Connecticut		§ 20-578; ADC 21a-254-6			§ 21a-254; ADC 21a-254-6		
Delaware	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	16 § 4798	
District of Columbia	Sec. 6	Sec. 6	Sec. 6	Sec. 6	Sec. 6		
Florida		§ 893.0551; ADC 64K-1.003	§ 893.0551; ADC 64K-1.003	§ 893.0551; ADC 64K-1.003	§ 893.0551; ADC 64K-1.003		
Georgia		§ 16-13-60		§ 16-13-60	§ 16-30-60		
Hawaii					§ 329-104		
Idaho		§ 37-2726	§ 37-2726	§ 37-2726	§ 37-2726; ADC 27-01-01-204		
Illinois		720 § 570/318		720 § 570/318	720 § 570/318		

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Indiana		§ 35-48-7-11.1	§ 35-48-7-11.1		§ 35-48-7-11.1	§ 35-48-7-11.1	
Iowa		ADC 657-37.4		§ 124.553; ADC 657-37.4	§ 124.553; ADC 657-37.4		
Kansas	§ 65-1685	§ 65-1685; ADC 68-21-5	§ 65-1685; ADC 68- 21-5	§ 65-1685; ADC 68-21-5	§ 65-1685; ADC 68-21-5		
Kentucky	§ 218A.202; 902 KAR 55:110	§ 218A.202	§ 218A.202	§ 218A.202	§ 218A.202		
Louisiana		§ 40:1007; ADC Tit. 46, Pt. LIII, §§ 2917 & 2921	§ 40:1007; ADC Tit. 46, Pt. LIII, §§ 2917 & 2921	§ 40:1007; ADC Tit. 46, Pt. LIII, § 2921	§ 40:1007; ADC Tit. 46, Pt. LIII, §§ 2917 & 2921		
Maine	22 § 7250; ADC 14-118, Ch. 11, § 7	22 § 7250; ADC 14-118, Ch. 11, § 7	22 § 7250; ADC 14- 118, Ch. 11, § 7	22 § 7250; ADC 14-118, Ch. 11, § 7	22 § 7250; ADC 14-118, Ch. 11, § 7		
Maryland	Health-Gen. § 21-2A-06; ADC 10.47.07.04	Health-Gen. § 21-2A-06; ADC 10.47.07.04	Health-Gen. § 21-2A- 06; ADC 10.47.07.04	Health-Gen. § 21-2A-06; ADC 10.47.07.04	Health-Gen. § 21-2A-06; ADC 10.47.07.04	Health-Gen. § 21-2A-06; ADC 10.47.07.04	
Massachusetts		94C § 24A; 105 CMR 700.012	94C § 24A; 105 CMR 700.012	94C § 24A; 66A § 2; 105 CMR 700.012	94C § 24A; 105 CMR 700.012		
Michigan		§ 333.7333a	§ 333.7333a		§ 333.7333a		
Minnesota	Admin.	§ 152.126	§ 152.126	§ 152.126	§ 152.126		
Mississippi	Admin.	§ 73-21-127	§ 73-21-127	§ 73-21-127	§ 73-21-127		
Missouri							
Montana	§ 37-7-1506	§ 37-7-1506	§ 37-7-1506	§ 37-7-1506	§ 37-7-1506		§ 39-71- 1110
Nebraska							

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Nevada		§ 453.1545	§ 453.1545	§ 453.1545	§ 453.1545		
New Hampshire		§ 318-B:35		§ 318-B:35	§ 318-B:35		
New Jersey		§ 45:1-46	§ 45:1-46		§ 45:1-46		
New Mexico	Admin.	ADC 16.19.29	ADC 16.19.29	ADC 16.19.29	ADC 16.19.29		
New York	PH § 3371	PH § 3371	PH § 3371	PH § 3343-a & 3371	PH § 3343-a & 3371		
North Carolina	§ 90-113.74	§ 90-113.74	§ 90-113.74	§ 90-113.74	§ 90-113.74		
North Dakota	Admin.	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03
Ohio		§ 4729.80; ADC 4729-37-08	§ 4729.80; § 5167.14; ADC 4729-37-08	§ 4729.80; ADC 4729-37-08	§ 4729.80; ADC 4729-37-08		§ 4729.80; ADC 4123-6-21.4
Oklahoma		63 § 2-309D			63 § 2-309D	63 § 2-309D	
Oregon	§ 431.966	§ 431.966; ADC 410-121-4020		§ 431.966; ADC 410-121-4020	§ 431.966; ADC 410-121-4020		
Pennsylvania							
Rhode Island		§ 21-28-3.32 ADC 31-2-1:3.0		§ 21-28-3.32	§ 21-28-3.32		
South Carolina		§ 44-53-1650	§ 44-53-1650	§ 44-53-1650	§ 44-53-1650		
South Dakota		§ 34-20E-7; ADC 2:51:32:07	§ 34-20E-7	§ 34-20E-7; ADC 2:51:32:06	§ 34-20E-7; ADC 2:51:32:04 & :05		
Tennessee	§ 53-10-306	§ 53-10-308; § 53-10-306; ADC 1140-11-.02	§ 53-10-306	ADC 1140-11-.02	§ 53-10-306; ADC 1140-11-.02	§ 53-10-306	
Texas		H&S § 481.076			H&S § 481.076		
Utah		§ 58-37f-301	§ 58-37f-301	§ 58-37f-301; R156-37f	§ 58-37f-301	§ 58-37f-301	§ 58-37f-301

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Vermont	18 § 4284	18 § 4284; ADC 12-5-21:3	18 § 4284	18 § 4284; ADC 12-5- 21:3	18 § 4284; ADC 12-5-21:3		
Virginia	§ 54.1-2523; 18 VAC 76-20- 60	§ 54.1-2523; 18 VAC 76-20-60	§ 54.1-2523; 18 VAC 76-20-60	§ 54.1-2523; 18 VAC 76- 20-60	§ 54.1-2523; 18 VAC 76-20-60		
Washington	ADC 246-470- 060	§ 70.225.040	§ 70.225.040	§ 70.225.040 ADC 246- 470-040	§ 70.225.040; ADC 246-470- 050		§70.225.040
West Virginia	§ 60A-9-5	§ 60A-9-5; ADC § 15-8-7	§ 60A-9-5		§ 60A-9-5; ADC § 15-8-7		
Wisconsin	ADC Pharm 18.11	ADC Pharm 18.11		ADC Pharm 18.11	ADC Pharm 18.09		
Wyoming		ADC AI PDSC Ch. 8, § 3		§ 35-7-1060; ADC AI PDSC Ch. 8, § 3	§ 35-7-1060; ADC AI PDSC Ch. 8, § 3		

<b>Types of Authorized Recipients:</b>	<b>Delegates</b>	<b>Law Enforcement</b>	<b>Judicial Officials</b>	<b>Physicians' Assistants</b>	<b>Health Care Agent</b>	<b>Resident Physician</b>	<b>State Toxicologist</b>
Alabama	§ 20-2-214	§ 20-2-214; ADC 420-7-2-.13		§ 20-2-214			
Alaska		§ 17.30.200			12 AAC 52.875		
Arizona		§ 36-2604; R4-23-503 & -505	§ 36-2604; R4-23-503 & -505				
Arkansas		§ 20-7-606 & -607; ADC 007.07.4-VI & -VII	§ 20-7-607; ADC 007.07.4-VII				
California	Bus. & Prof. § 209	H&S § 11165	H&S § 11165				
Colorado		§ 12-42.5-404; ADC 719-1:23.00.00	§ 12-42.5-404; ADC 719-1:23.00.00		3 CCR 719-1:23.00.00	§ 12-42.5-404	
Connecticut		ADC 21a-254-6					
Delaware	16 § 4798	16 § 4798	16 § 4798				
District of Columbia	Sec. 5	Sec. 6	Sec. 6				
Florida		§ 893.055 & .0551; ADC 64K-1.003	§ 893.055 & .0551; ADC 64K-1.003		§ 893.0551; ADC 64K-1.003		
Georgia		§ 16-13-60	§ 16-13-60				
Hawaii		§ 329-104; ADC § 23-200-22	§ 329-104	§ 329-104			
Idaho	Admin.	§ 37-2726	§ 37-2726				
Illinois		720 § 570/318	720 § 570/318				
Indiana	§ 35-48-7-11.1	§ 35-48-7-11.1	§ 35-48-7-11.1				§ 35-48-7-11.1
Iowa	§ 124.553; ADC 6567-37.2 & -37.4	ADC 657-37.4	§ 124.553; ADC 657-37.4		ADC 657-37.4		

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Kansas	ADC 68-21-5	§ 65-1685; ADC 68-21-5	§ 65-1685; ADC 68-21-5		ADC 68-21-5		
Kentucky	§ 218A.202	§ 218A.202; § 218A.240; 902 ADC 55:110	§ 218A.202		§ 218A.202		
Louisiana	§ 40:1007	§ 40:1007; ADC Tit. 46, Pt. LIII, § 2921	§ 40:1007; ADC Tit. 46, Pt. LIII, § 2921				
Maine	ADC 14-118, Ch. 11, § 7	Website			ADC 14-118 Ch. 11, § 7		
Maryland	Health-Gen. §21-2A-06; ADC 10.47.07.02 & .04	Health-Gen. § 21-2A-06; ADC 10.47.07.04			ADC 10.47.07.04		
Massachusetts	94C § 24A	94C § 24A; 105 CMR 700.012	94C § 24A; 105 CMR 700.012		66A § 2		
Michigan		§ 333.7333a	§ 333.7333a				
Minnesota	§ 152.126; § 245A.192	§ 152.126			§ 152.126		
Mississippi		§ 73-21-127 & § 41-27-187	§ 41-29-187 & 73-21-127				
Missouri							
Montana	ADC 24.174.1701	§ 35-7-1506					
Nebraska							
Nevada		§ 453.1545 & § 453.151	§ 453.1545 & § 453.151				
New Hampshire		§ 318-B:35					
New Jersey		§ 45:1-46	§ 45:1-46				
New Mexico	ADC 16.19.29	ADC 16.19.29	ADC 16.19.29	ADC 16.19.29			
New York	PH § 3343-a; 10 ADC 80.63	PH § 3371; 10 ADC § 80.107	PH § 3371; 10 ADC § 80.107		PH § 3343-a & 3371		

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

North Carolina	§ 90-113.74	§ 90-113.74	§ 90-113.74				
North Dakota	Admin.	§ 19-03.5-03	§ 19-03.5-03	§ 19-03.5-03		§ 19-03.5-03	
Ohio	§ 4729.80	§ 4729.80; ADC 4729-37-08	§ 4729.80				
Oklahoma		63 § 2-309D	63 § 2-309D				
Oregon	§ 431.966	§ 431.966; ADC 410-121-4020					
Pennsylvania		18 § 9102 & 35 § 780-137	18 § 9102 & 35 § 780-137				
Rhode Island		§ 21-28-3.32 ADC 31-2-1:3.0					
South Carolina		§ 44-53-1650	§ 44-53-1650				
South Dakota	Admin.	§ 34-20E-7; ADC 20:51:32:08	§ 34-20E-7; ADC 20:51:32:08 & :09		ADC 20:51:32:06		
Tennessee	§ 53-10-306 & -302	§ 53-10-306 & -309; ADC 1140-11-.02	§ 53-10-306; ADC 1140-11-.02				
Texas	H&S § 481.076	H&S § 481.076; 37 ADC § 13.82	H&S § 481.076; 37 ADC § 13.82	H&S § 481.076			
Utah	§ 58-37f-301; R156-37f	§ 58-37f-301; R156-37f	§ 58-37f-301; R156-37f		ADC R156-37f		
Vermont	18 §§ 4282 & 4284	18 §§ 4282 & 4284; ADC 12-5-21:3 & :4					
Virginia	§ 54.1-2523.2	§ 54.1-2523; 18 VAC 76-20-50	§ 54.1-2523; 18 VAC 76-20-50				
Washington	ADC 246-470-050	§ 70.225.040	§ 70.225.040		ADC 246-470-040		
West Virginia	§ 60A-9-5; ADC § 15-8-7	§ 60A-9-5; ADC § 15-8-7	§ 60A-9-5; ADC § 15-8-7				

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Wisconsin	ADC Pharm 18.09	§ 146.82; ADC Pharm 18.11	§ 146.82		ADC Pharm 18.11		
Wyoming		§ 35-7-1060; ADC AI PDSC Ch. 8, § 3			ADC AI PDSC Ch. 8, § 3		



<b>Types of Authorized Recipients:</b>	<b>Probation/ Parole Officer</b>	<b>Health Care Payment/ Benefit Provider/Insurer</b>	<b>Peer Review Committee</b>	<b>Attorney on Behalf of Patient</b>	<b>Quality Improvement Committee of Hospital</b>	<b>Department of Health</b>
Alabama						
Alaska						
Arizona						
Arkansas						
California						
Colorado						
Connecticut						
Delaware						
Florida						
Georgia				§ 16-13-60		
Hawaii						
Idaho				§ 37-2726 (until July 1, 2014)		
Illinois						
Indiana						
Iowa						
Kansas			§ 65-1685			
Kentucky	§218A.202					
Louisiana						
Maine						
Maryland						
Massachusetts						
Michigan		§ 333.7333a				
Minnesota						
Mississippi						
Missouri						
Montana						
Nebraska						
Nevada				§ 453.1545		

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

New Hampshire						
New Jersey						
New Mexico						ADC 16.19.29
New York						PH § 3371
North Carolina						
North Dakota	§ 19-03.5-03		§ 19-03.5-03			
Ohio						
Oklahoma						63 § 2-309D
Oregon						
Pennsylvania						
Rhode Island						
South Carolina						
South Dakota		§ 34-20E-7	§ 34-20E-7			
Tennessee					§ 53-10-306	
Texas						
Utah						§ 58-37f-301
Vermont						
Virginia			§ 54.1-2523			
Washington						
West Virginia						
Wisconsin						
Wyoming						

	<b>Types of Authorized Recipients: Commissioner of Public Safety</b>	<b>Types of Authorized Recipients: Director of the Department of Corrections</b>	<b>Types of Authorized Recipients: Third Party with Signed Consent Form</b>	<b>Evaluation of PMP: Report to Legislature</b>	<b>Evaluation of PMP: Advisory Committee, Task Force, etc.</b>	<b>No Requirement to Access</b>	<b>Data Collection Interval</b>
Alabama					§ 20-2-212	§ 20-2-214	Weekly
Alaska				§ 17.30.200		§ 17.30.200; 12 AAC 52.855	Monthly
Arizona					§ 36-2603		Weekly
Arkansas					§ 20-7-605; ADC 007.07.4-V		Weekly
California							Weekly
Colorado							Twice monthly
Connecticut					§ 21a-254a		Weekly
Delaware				16 § 4798			Daily
District of Columbia					Sec. 3		Daily
Florida							7 days
Georgia					§ 16-13-61	§ 16-13-63	Weekly
Hawaii							7 days
Idaho			§ 37-2726 (eff. July 1, 2014)				Weekly
Illinois					720 § 570/320	720 § 570/314.5 & 570/318	7 days
Indiana						§ 35-48-7-11.1	7 days
Iowa				§ 124.554 & .555	§ 124.555	§ 124.553	Weekly
Kansas				§ 65-1691	§ 65-1689, -1690, -1691	§ 65-1688	24 hours
Kentucky					Exec. order		Daily

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

Louisiana				§ 40:1010	§ 40:1005; ADC Tit. 46, Pt. LIII § 2909		7 days
Maine				Resolution	PMP Admin.		Weekly
Maryland				Health-Gen. § 21-2A-05	Health-Gen. § 21-2A-05 & - 07	Health-Gen. § 21-2A-04; ADC 10.47.07.08	3 days
Massachusetts				94C § 24A	105 ADC 700.012		7 days
Michigan				§ 333.7112 & .7113	§ 333.7112 & .7113		Twice monthly (until 6/30/2014); daily (as of 7/1/2014)
Minnesota				§ 152.126	§ 152.126	§ 152.126	Daily
Mississippi							7 days
Missouri							N/A
Montana				§ 37-7-1514	§ 35-7-1510		Weekly
Nebraska							N/A
Nevada					§ 453.1545		Weekly
New Hampshire					§ 318-B:38		7 days
New Jersey						§ 45:1-46	Twice monthly
New Mexico							7 days
New York				PH § 3309-a	PH § 3309-a		Real time (interpreted to mean within 24 hours)
North Carolina					PMP Admin.		3 days
North Dakota					§ 19-03.5-07	§ 19-03.5-05	Daily
Ohio				§ 4729.85			Weekly for pharmacies;

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501

							monthly for wholesalers
Oklahoma						63 § 2-309D	Real time
Oregon <sup>4</sup>				§ 431.962	§ 431.976 & .978	§ 431.966	7 days
Pennsylvania							Monthly
Rhode Island							Monthly
South Carolina						§ 44-53-1680	Daily
South Dakota					§ 34-20E-15, -16, -17	§ 34-20E-11	Weekly
Tennessee			ADC 1140-11-.02	§ 53-10-309	§ 53-10-303		7 days
Texas				H&S §§ 481.351 & 481.354	H&S §§ 481.351 - .354		7 days
Utah			R156-37f				Weekly; daily for pilot program
Vermont	18 § 4284			Uncodified	Uncodified		Weekly
Virginia					§ 54.1-2520		7 days
Washington		§ 70.225.040					Weekly
West Virginia				§ 60A-9-5	§ 60A-9-5		24 hours
Wisconsin		ADC Pharm 18.11				§ 450.19	7 days
Wyoming			§ 35-7-1060 & ADC AI PDSC Ch. 8, § 3			ADC AI PDSC Ch. 8, § 3	7 days

<sup>4</sup> Oregon does not require a report to the state legislature. It does require that the Oregon Health Authority, the body responsible for the operation of the PMP, make an annual report to the Prescription Monitoring Program Advisory Commission.

© 2014 Research is current as of March 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software, individual state legislative websites and direct communications with state PDMP representatives. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501